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Objective. To examine the eﬀectiveness of oral vitamin D3 (400IU) supplementation on the nutritional vitamin D status of
breastfeeding infants. Design. As part of a larger ongoing vitamin D RCT trial of lactating women, infants of mothers assigned
to control received 1 drop of 400IU vitamin D3/day starting at one month of age. Infant 25(OH)D levels (mean ± S.D.) were
measured by RIA at visits 1, 4, and 7. Results. The infant mean ± S.D. 25(OH)D at baseline was 16.0 ± 9.3ng/mL (range 1.0–40.8;
n = 33); 24 (72.7%) had baseline levels <20ng/mL (consistent with deﬁciency). The mean levels increased to 43.6 ± 14.1 (range
18.2–69.7) at 4 months and remained relatively unchanged at month 7: 42.5 ± 12.1ng/mL (range 18.9–67.2). The change in values
between 1 and 4 months and 1 and 7 months was statistically signiﬁcant (P ≤ .0001), and despite a decrease in dose per kilogram,
values were not signiﬁcantly diﬀerent between months 4 and 7 (P = .66). Conclusions. Oral vitamin D3 supplementation as an oil
emulsion was associated with signiﬁcant and sustained increases in 25(OH)D from baseline in fully breastfeeding infants through
7m o n t h s .
1.Introduction
Among breastfed infants, the risk of vitamin D deﬁciency
is signiﬁcant [1, 2]. Human milk, though replete in most
nutrients, is sorely lacking in vitamin D at the current
maternal intake recommendation of 400IU/day. Human
milk’s total vitamin D or its antirachitic activity obtained
from mothers receiving 400IU/day typically contains 33–
68IU/L, far below the estimated daily infant requirement
of 400IU/L [3–5], the necessary level for the prevention of
rickets [1]. Therefore, oral supplementation or suﬃcient sun
exposure is necessary to ensure adequate vitamin D status
for proper calcium absorption and bone mineralization [3–
6]. Recent research has also linked vitamin D to innate
immunity [7–9]. Furthermore, vitamin D deﬁciency has
been associated witha number of disease states including but
certainly not limited to rheumatoid arthritis [10], multiple
sclerosis [11–14], type I and II diabetes [15–19], Crohn’s
disease[20],cardiovasculardisease[21,22],andanumberof
cancers [23, 24]. With this knowledge, it is clear that vitamin
D supplementation of the breastfed infant is necessary and
recommended by the American Academy of Pediatrics and
the Canadian Pediatrics Society [5, 25].
The revised statement by the American Academy of
Pediatrics [26] brings forth the question of whether or
not vitamin D-only preparations are as eﬀective as the
time-honored use of infant multivitamin preparations in
achieving adequate vitamin D status in breastfed infants.
In the past, only multivitamin preparations were available
for dispensing to infants; however, this resulted in breastfed
infants being given other vitamins that were not, for the
vast majority, necessary. During recent years, vitamin D-
only preparations have become available, some of which are
aqueous and others which are oil-based preparations.2 International Journal of Endocrinology
As part of an ongoing vitamin D supplementation trial
of fully lactating women and their infants, we sought to
determine whether a dosing regimen that utilizes an oil
emulsion of one drop per day to deliver 400IU/day is
eﬀective in raising infant 25(OH)D levels from baseline.
We hypothesized that one drop per day dosing regimen
would be easier to administer than other preparations as
the drop could be placed on a ﬁnger and then applied to
the infant’s tongue or mouth or on the mother’s nipple just
prior to suckling. While the parent randomized clinical trial
will not be completed until 2011, it is essential to report
preliminary data on the eﬀectiveness of one drop per day
dosingofvitaminDtoaidcliniciansintheirdecision-making
process concerning vitamin D preparations for infants. We
report the ﬁndings of 33 infants who completed the study
and who were given 400IU vitamin D3/day in a blinded
fashion.
2. Methods
2.1. Subjects. Approval for this study was granted by the
Institutional Review Boards for Human Subjects of the
Medical University of South Carolina (MUSC), HR number
16536; and the University of Rochester (U of R), HR number
RSRB00014460;andtheGeneralClinicalResearchCentersof
MUSC (GCRC; Protocol number 752) and U of R (Protocol
GCRC; Protocol number 1129 ). Fully lactating mothers [27]
within 4–6 weeks’ postpartum were eligible for inclusion in
the study if they planned to continue full breastfeeding for
the next six months. Following their written, informed con-
sent, the subjects were randomly divided into three groups at
each study site. Exclusion criteria included preexisting type
I or type II diabetes, hypertension, parathyroid disease, and
uncontrolled thyroid disease. Subjects were compensated for
their participation with gift cards given at the end of each
visit.
2.2. Study Design. This was part of an ongoing randomized,
double-blind, and placebo control trial of lactating mothers
and their infants. Following written informed consent,
mothers were randomized to one of three vitamin D supple-
mentation regimens: Group 1: 400IU vitamin D3/day (0IU
vitamin D3—placebo and 1 prenatal vitamin containing
400IU vitamin D3), Group 2: 2,400IU vitamin D3/day
(2,000IU vitamin D3 and 1 prenatal vitamin containing
400IU vitamin D3), or Group 3: 6,400IU vitamin D3/day
(6,000IU vitamin D3 and 1 prenatal vitamin containing
400IU vitamin D3). Only the results of the infants random-
ized to the control group are reported here.
The mothers also were provided in a blinded fashion
with a liquid supplement with the instructions to give one
drop per day to their nursed infants. Mothers in Group 1
gave their infants one drop (400IU vitamin D3)p e rd a yo fa
commercially available oil emulsion (Bio-D-Mulsion, Biotics
ResearchLaboratories,Rosenberg,TX).ThevitaminDstatus
ofthoseinfantsinthecontrolgroupwhoreceived400IU/day
vitamin D3 was measured by circulating 25(OH)D at 1, 4,
and 7 months of age. Study participants and research staﬀ
have remained blinded to the assignment group throughout
the study.
2.3. Use of Formula. Because of the potential confounder
of proprietary formulas that contain 400IU/L vitamin D,
each mother was given up to six 4-oz bottles per month
of vitamin D-free formula with the instructions to avoid
use of any formula but if there was a need to supplement,
the vitamin D-free formula prepared by Mead-Johnson,
Evansville, IN was used. Each mother was to record any
vitamin D-free and/or regular formulas use during the study
period. Therefore, the dietary source of vitamin D in these
infants came from the vitamin D supplement provided.
2.4. Sunlight Exposure. A diary of sunlight exposure of
the mother and her infant was kept. In order to quantify
any possible sunlight exposure contributing to endogenous
generation of vitamin D3, degrees of skin pigmentation of
the underarm, and forearm were recorded at each visit.
2.5. Degree of Skin Pigmentation. Skin pigmentation changes
were monitored monthly in mother and infant using the
SmartProbe 400 (IMS, Inc., Milford, CT), a spectropho-
tometer device that measures degrees of pigmentation on a
continuous scale from 0 to 100, 0 being absolute black and
100 being absolute white. Each mother had pigmentation
measurements recorded from her exposed forearm, under-
arm, and stomach, with 2 readings averaged and recorded.
Each infant had pigmentation measurements recorded from
the forearm and upper thigh. Of note, mothers were
instructed to use sunscreen if outdoors for more than 15
minutesandtoavoiddirectsunlightexposureoftheirinfants
during the ﬁrst six months.
The diﬀerence between forearm and underarm is an
indirect measure of sunlight exposure or tanning and
was tracked over time. Use of a spectrophotometer has
been demonstrated to be eﬀective as an objective, repro-
ducible measurement in determinations of sunlight expo-
sure [28].The spectrophotometer allows measurement of
color changes in the skin speciﬁcally due to UV radiation
[29].
2.6. Season. Mothers and their infants were enrolled
throughout the year. The date and season of each visit were
r e c o r d e d .T h es e a s o n sw e r ed e ﬁ n e da sS p r i n g( M a r c h2 1 –
June 20), Summer (June 21–September 20), Fall (September
21–December 20), and Winter (December 21–March 20).
Sunny months at latitude 32
◦N based on ultraviolet light
indices occur from April through October. Relative non-
sunny months comparatively occur from November through
March. At latitude 43
◦N, sunny months occur May through
mid-September and relative non-sunny months occur from
mid-September through April.
2.7. Laboratory Measurements. For this component of the
study, circulating 25(OH)D3 was measured in ng/mL in
infant blood samples by established methods [30] in the
laboratory of Dr. Bruce Hollis, MUSC.International Journal of Endocrinology 3
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Figure 1
2.8. Maintaining Study Blindness. To maintain study staﬀ
and investigator blinding, the data coordinating center
provided the data to the study investigators and the Data
Safety & Monitoring Committee in a blinded manner.
2.9.StatisticalMethods. Theprimaryanalysiswastoexamine
the changes in 25(OH)D between the three time periods
and secondarily to determine whether the season when the
sample was obtained was associated with any changes in
25(OH)D [31]. 25(OH)D, the primary outcome variable,
wasexpressedasthemean ±S.D.andtherangeforthegroup
at each of the three time points. Paired Student’s t-test and
repeated measures ANOVA were performed on the data. In
addition, a repeated measure ANOVA was performed on the
data at the three time points. Signiﬁcance was set at .05 a
priori.
3. Results
In this ongoing vitamin D supplementation trial of lactating
women and their infants, 54 were enrolled in the study and
were randomized to the control group in a blinded fashion.
Of the 54 women and their infants, 33 have completed the
study through visit 7, 39 have completed through visit 4, and
15 had stopped participation between visits 1 and 4, due to
cessation of breastfeeding.
As shown in Table 1 and Figure 1, analyzing all val-
ues per study visits 1,4,and7, therewasasigniﬁcant rise
in 25(OH)D levels in those infants randomized to the
400IU vitamin D3/one drop/day regimen. Of the 33 infants
who have completed the study, the mean levels increased
from 16.0±9.3ng/mL (baseline; range 1.0–40.8ng/mL;
median 13.4) to 43.6±14.1ng/mL (range 18.2–69.7) at
4 months and remained relatively unchanged at month
7:42.5±12.1ng/mL (range 18.9–67.2). As deﬁned by cir-
culating 25(OH)D levels <20ng/mL, of the 33 infants, 24
(72.7%) had evidence of deﬁciency at one month of age.
The change in values between 1 and 4 months and 1 and
7 months was statistically signiﬁcant (P ≤ .0001). As
predicted, there were no statistically signiﬁcant diﬀerences
between months 4 and 7 (P = .66). Repeated measures
ANOVA indicated overall signiﬁcance (P<. 0001). The
diﬀerence was unaﬀected by seasonal variation (Table 2).
There was no toxicity observed in the infants based on serum
calcium, phosphorus, and creatinine levels. In addition,
there were no adverse health eﬀects attributed to vitamin D
supplementation.
When examining the 400IU vitamin D/day dose on a
weight basis, there was a signiﬁcant change in IU/kg over
the time for the 33 infants who completed the study: at
visit 1, the infants were receiving 88.9±10.5IU/kg; at visit
4, they were receiving 59.7±6.6 IU/kg; and at visit 7, they
were receiving 50.5±6.0 IU/kg (P<. 0001). Despite the
decrease in dose on a per kilogram basis, as mentioned
earlier, the infant mean circulating 25(OH)D levels were not
signiﬁcantly diﬀerent between visit 4 and 7. After controlling
for season and skin pigmentation changes due to sunlight
exposure, results remained signiﬁcant.
4. Discussion
Because the preliminary results of this arm of the trial
are important for decision-making in the current clinical
environment, we report here the interim results of an
ongoingvitaminDsupplementationtrialoflactatingwomen
and their infants. In this ongoing study of lactating women
and their infants who were randomized to one of three
treatment groups, we sought to determine whether the one
drop per day of an oil emulsion vitamin D3 preparation
is eﬀective in raising the infants’ levels to the desired
target of >30ng/mL (∼80nmol/L). Infant’s 25(OH)D levels
consistently and signiﬁcantly increased to a plateau by three
months of therapy on the daily oil emulsion preparation
dispensed as one drop per day to deliver 400 IU. Over-
all, the infant’s circulating 25(OH)D levels increased 37%
above baseline. There were no adverse events associated
with the prescribed vitamin D supplementation. While not
powered to assess safety at this juncture, it is important
to note that, thus far, there have been no increased rates
of infection in the infants or adverse health eﬀects that
could be attributed to vitamin D supplementation in this
cohort.
Another important ﬁnding in this study is that the
majority of infants enrolled in this cohort of exclusively
breastfed infants had vitamin D deﬁciency (deﬁned as
circulating 25(OH)D levels <20ng/mL) at one month of age.
Infant vitamin D levels in exclusively breastfed infants reﬂect
maternal vitamin D status, and given that the majority of
the mothers in this cohort present with circulating 25(OH)D
levels <30ng/mL, it is not surprising that the infants who
are almost solely dependent on the mother for their vitamin
D have corresponding deﬁciency. Until it can be determined
what amount of vitamin D supplementation in mothers will
eﬀectively and safely increase and/or maintain the vitamin
D status in her breastfed infant, we must rely on vitamin D
supplementation of the infant to prevent deﬁciency. Thus,
our ﬁndings in this study and our earlier studies [4, 32]4 International Journal of Endocrinology
Table 1: Infant weight, vitamin D status, and dosage per body weight.
Variable Visit 1 (n = 33) Visit 4 (n = 33) Visit 7 (n = 33)
Infant wt (mean±S.D.) 4.6±0.52kg 6.8±0.75kg 8.0±.98kg
Total circulating 25(OH)D (ng/mL) 16.0±9.3 43.6±14.1 42.5±12.1
IU vitamin D/body wt (kg) 88.9±10.5 59.7±6.6 50.5±6.0
Table 2: Circulating 25(OH)D (ng/mL) at visits 1, 4, and 7 by
season. Sunny months at latitude 32
◦N based on ultraviolet light
indices occur from April through October. Relative nonsunny
months comparatively occur from November through March.
25(OH)D
(ng/mL)
25(OH)D
(ng/mL)
25(OH)D
(ng/mL)
Visit 1 Visit 4 Visit 7
Sunny months 18.5 46.0 48.0
Nonsunny months 13.2 42.1 37.3
support the recent AAP recommendation of starting vitamin
Dsupplementationinallbreastfedinfantswithintheﬁrstfew
days after delivery [26].
Concerns about dosing infants with any medication,
particularly as a single drop, are warranted. The greatest
risk appears when a parent is not instructed on how to
give a medication or does not receive the full instruction on
proper dispensing. We have found in our study of lactating
women that demonstrating how to give the drop is the best
method of teaching proper dispensing. Mothers are asked
to demonstrate how to give the drop prior to leaving the
research outpatient clinic, and this method has been found
to be eﬀective.
Our ﬁndings support the premise that an oil emulsion
delivered as a single drop is well-tolerated and absorbed
with a consistent increase in circulating 25(OH)D on the
vitamin D supplementation during a three-month interval
that was sustained during the next three-month interval.
While prescription of a vitamin or medication and changes
in blood levels of that vitamin or medication, in this case,
vitamin D does not prove direct causality, the change in
circulating 25(OH)D status was independent of season. In
addition,despitethenormalgrowthoftheinfantsduringthis
six-month period, on a per kilogram basis, the 400IU/day
dose was adequate in helping the infant maintain adequate
vitamin D status during the six-month study period.
Limitations of this study include its small sample size.
This study is designed to enroll 126 subjects into the control
arm. To date, 54 subjects have been enrolled and 33 have
completed the study. We acknowledge that this interim
report is based on the ﬁrst 33 to have completed this ongoing
trial and that while this represents ∼61% of the 54 enrolled
and 26% of the total projected cohort, we believe that
the results are generalizable since timing of enrollment is
random. There would be no underlying systematic bias that
would suggest that the results of the ﬁrst 33 subjects would
diﬀer from the middle 33 or the last 33, especially when
seasonalityiscontrolledasapotentialconfounder,whichwas
done.
Another limitation of this study is the lack of a placebo
control group. While a group of infants that received
placebo would allow for more reﬁned statistical analyses, it
is deemed unethical by the investigators and the IRB not
to supplement the infants with what is now the standard of
care for vitamin D supplementation of infants and children
in both the U.S. and Canada (see AAP statement 2008 [5]
and Canadian Paediatric Society statement 2007 [33]). The
direct eﬀect of the vitamin D supplementation is supported
by the following: in this trial, of the mothers who were
randomized to receive 2400IU vitamin D/day, there was
insuﬃcient transfer of vitamin D in their milk and 31%
of those breastfed infants required open label vitamin D
supplementation at the 4th month visit compared with 6%
in the control group and 5% in the 6400IU vitamin D
supplementation group. As a result, the 2400IU arm of the
study was stopped in February 2008 (unpublished data).
Clearly, the 400IU/day group of infants (presented here) had
improved vitamin D status based on their therapy that was
not seen in the 2400IU group of infants, who were receiving
placebo and whose only source of vitamin D was maternal
breast milk that has signiﬁcantly lower levels than that of the
6400 IU group.
In summary, a single drop oil emulsion vitamin D
preparation appears to be an eﬀective method to deliver
vitamin D3 to a breastfed infant. The safety of this regimen
beyond this small cohort remains to be determined. Further
evaluation of this method also is warranted in infants who
have underlying disease states.
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